SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

Lesley Bowman

Senior Scientist

Lesley is responsible for upstream and downstream process development activities for our latest viral antigen vaccine candidate to combat human cytomegalovirus (CMV).

She joined SpyBiotech in March 2019 from the Sir William Dunn School of Pathology, a department of the University of Oxford, where for five years she worked in collaboration with academic and industrial partners on the pre-clinical development of vaccines that target Shigella, an infectious bacteria that causes severe diarrhea and dysentery.

Lesley holds a PhD in Microbiology from the University of Sheffield.

Back to team

Read more about our pipeline and the diseases we are working to eradicate.

Our Pipeline